cannabidiol (CBD), the key cannabinoid component in dozens of Medical Marijuana, Inc. portfolio products. The University of Cologne in Germany conducted a study on the effectiveness of CBD versus standard anti-psychotics. PsychCentral.com outlines the results of this groundgreaking CBD-only treatment for schizophrenia patients. From the article:
-
“The results were amazing,” said Daniel Piomelli, Ph.D., professor of pharmacology at the University of California-Irvine and a co-author of the study. “Not only was [CBD] as effective as standard antipsychotics, but it was also essentially free of the typical side effects seen with antipsychotic drugs.”
